MindBio Therapeutics

MindBio Therapeutics is conducting clinical research exploring the effects of microdosing psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opioid addiction.


MindBio is working with researchers at the University of Auckland on an ongoing phase I clinical trial exploring the effects of microdosing LSD for the treatment of depression. The company plans to conduct a phase II study that will assess the effects of microdosing LSD in tandem with psychotherapy in late-stage cancer patients.

In August 2021, MindBio was acquired by Blackhawk Growth Corp which help the company to scale their operations and advance its psychedelic portfolio. The company has started preparations to spin out from Blackhawk to list MindBio in its own right on the Canadian Securities Exchange (CSE) in the near future.

“The current treatment regimens for mental health management are not working in the way that society expects, so at MindBio we are working on a range of novel drug development and technological innovations that are being clinically tested to determine their safety and efficacy in order to better treat these debilitating mental health conditions.”

Company Information

MindBio Therapeutics Website

March, 2021


B2C Pharmaceutical Biotech

Compounds of Interest

Topics of Interest

Explore more company info with a Tree membership

📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates

Explore memberships


HQ / Office Melbourne VIC, Australia